Thursday, November 19, 2020 1:15:36 PM
The denial of the reexamination requested by Mylan was a big deal:
https://www.1600ptab.com/wp-content/uploads/sites/27/2018/12/IPR2018-01143-DDI.pdf
Also, if you read further down the page below this intro, about
half (or more) of the cases have settled.
The reason why I find this important is because the '218 patent
covers Xarelto's dosing techniques until 2034. Bears on Bayer
say the Xarelto money will dry up after 2024, but this looks
like Xarelto protection should be extended for 10 more years.
Also, as a recent buyer of the stock, I am expecting the Monsanto
litigation to completely settle for $12 billion - that's looking
better than before.
Here's the '218 litigation:
<<Beginning in April 2017, JPI and Bayer Intellectual Property GmbH and Bayer AG (collectively, Bayer AG) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO® before expiration of Bayer AG’s United States Patent No. 9,539,218 (’218) relating to XARELTO®. JPI is the exclusive sublicensee of the asserted patent.
The following generic companies are named defendants: Alembic Pharmaceuticals Limited, Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. (Alembic); Aurobindo; Breckenridge; InvaGen; Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin); Micro; Mylan; Sigmapharm; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc. (collectively, Taro) and Torrent. Lupin counterclaimed for declaratory judgment of noninfringement and invalidity of United States Patent No. 9,415,053, but Lupin dismissed its counterclaims after it was provided a covenant not to sue on that
patent. Aurobindo, Taro, Torrent, Micro, Breckenridge, InvaGen, Sigmapharm, Lupin and Alembic have agreed to have their cases stayed and to be bound by the
outcome of any final judgment rendered against any of the other defendants. The ’218 cases have been consolidated for discovery and trial. The trial began in April
2019 and closing arguments were heard in June 2019.>>
<<In October 2019, JPI and Bayer entered into a settlement agreement with Mylan. In November 2019, JPI and Bayer entered into a settlement agreement with
Breckenridge. In December 2019, JPI and Bayer entered into settlement agreements with each of Accord, Micro, Sigmapharm, Sunshine, and Torrent. In January
2020, JPI and Bayer entered into a settlement agreement with Macleods.
The consolidated ’218 cases involving Alembic, Aurobindo, InvaGen, Lupin, Taro, and Teva, and have been stayed until March 2020.>>'
Page 92 at the bottom:
https://johnsonandjohnson.gcs-web.com/sec-filings/sec-filing/10-k/0000200406-20-000010
Recent BAYRY News
- Bayer Names Nelson Ambrogio as New Head of Radiology Business • Dow Jones News • 01/22/2024 02:26:00 PM
- Bayer's Menopause Drug Elinzanetant Met Primary Endpoints in Phase 3 Studies • Dow Jones News • 01/08/2024 08:05:00 AM
- Bayer's Monsanto Ordered to Pay $857 Million Over Chemicals in Washington State School, Bloomberg Reports • Dow Jones News • 12/19/2023 10:12:00 AM
- Trending: Bayer Shares Tank After Key Clinical Trial Halted Early, Roundup Verdict • Dow Jones News • 11/20/2023 03:43:00 PM
- Bayer Shares Tumble After Clinical Trial Failure, Roundup Case Loss • Dow Jones News • 11/20/2023 10:20:00 AM
- Bayer Stops Late-Stage Study for Stroke Prevention Due to Lack of Efficacy • Dow Jones News • 11/20/2023 07:22:00 AM
- Bayer Pulling Lymphoma Drug Aliqopa From U.S. • Dow Jones News • 11/13/2023 03:58:00 PM
- Bayer Gets CHMP Backing for Higher-Dose Eylea in Two Major Retinal Eye Diseases • Dow Jones News • 11/10/2023 03:00:00 PM
- Bayer Weighs Structural Changes But Rules Out Three-Way Split -- 3rd Update • Dow Jones News • 11/08/2023 10:32:00 AM
- Bayer Weighs Structural Changes But Rules Out Three-Way Split -- 2nd Update • Dow Jones News • 11/08/2023 08:40:00 AM
- Bayer Considers Structural Changes But Rules Out Three-Way Split -- Update • Dow Jones News • 11/08/2023 07:41:00 AM
- Bayer Looks at Options to Overhaul Structure • Dow Jones News • 11/08/2023 07:17:00 AM
- Bayer Launches New Rice Cultivation Method it Says Can Cut Emissions by 45% -- OPIS • Dow Jones News • 10/16/2023 10:03:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM